Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

Plasma F2 Isoprostanes

Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes

  1. Michael J. Sampson, MD1,
  2. Nitin Gopaul, PHD2,
  3. Isabel R. Davies, PHD3,
  4. David A. Hughes, PHD3 and
  5. Martin J. Carrier, PHD2
  1. 1Bertram Diabetes Research Unit, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, U.K.
  2. 2William Harvey Research Institute, St. Bartholomews Hospital, London, U.K.
  3. 3Institute of Food Research, Norwich Research Park, Colney, Norwich, U.K.
    Diabetes Care 2002 Mar; 25(3): 537-541. https://doi.org/10.2337/diacare.25.3.537
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes

    Abstract

    OBJECTIVES—Acute hyperglycemia in type 2 diabetes increases the generation of plasma 8-epi-prostaglandin F2 (8-epi-PGF2α) isoprostane, a sensitive direct marker of in vivo free radical oxidative damage to membrane phospholipids.

    RESEARCH DESIGN AND METHODS—A total of 21 patients with type 2 diabetes underwent an oral 75-g glucose tolerance test. Plasma 8-epi-PGF2α isoprostane concentrations (by gas chromatography [GC]/mass spectrometry [MS]), intralymphocyte reduced-to-oxidized glutathione ratios, and plasma total antioxidant capacity were measured at baseline and 90 min after glucose loading.

    RESULTS—Plasma 8-epi-PGF2α isoprostane concentrations rose significantly (P=0. 010) from 0.241± 0.1 to 0.326± 0.17 ng/l after 90 min. Intracellular oxidative balance and plasma antioxidant capacity did not change in either group.

    CONCLUSIONS—Plasma concentrations of 8-epi-PGF2α isoprostane increase during acute hyperglycemia in type 2 diabetes, providing direct evidence of free radical–mediated oxidative damage and demonstrating a pathway for an association between acute rather than fasting hyperglycemia and macrovascular risk in type 2 diabetes.

    • ABTS, 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid
    • BHT, butylated hydroxytoluene
    • 8-epi-PGF2α, 8-epi-prostaglandin F2α
    • GC, gas chromatography
    • GSH, glutathione
    • MS, mass spectrometry
    • TAOS, total antioxidant status

    Acute hyperglycemia after a meal or glucose load may be an independent predictor of vascular event rates in type 2 diabetes or impaired glucose tolerance (1–4). One possible mechanism for such a relationship is increased generation of reactive oxygen species during acute hyperglycemia, leading to acute oxidative damage to the vascular endothelium, cell membranes, and lipoprotein components (5).

    It has proven difficult to detect increased plasma free radical generation in human diabetes using, for example, electron spin resonance methods (6), and the usefulness of other surrogate markers of oxidative stress has been questioned (7). The F2α isoprostanes appear to be the best available marker of lipid peroxidation in vivo (8). These stable eicosanoids are produced by the enzyme-independent free radical oxidation of arachidonic acid in membrane phospholipids and lipoproteins and are generated in conditions of increased oxidative stress in animal and human models (8–10). Plasma and urine concentrations of F2α isoprostanes are increased in type 2 diabetes (11,12), in direct relationship to measures of chronic hyperglycemia (12). It is unknown whether acute hyperglycemia influences F2 isoprostane generation in type 2 diabetes.

    We hypothesized that acute hyperglycemia after a glucose load in people with type 2 diabetes would lead to acutely increased generation of plasma F2 isoprostanes, and that this would suggest one possible pathway between acute hyperglycemia, associated free radical damage, and macrovascular disease in type 2 diabetes.

    RESEARCH DESIGN AND METHODS

    Patient selection

    After local ethical committee approval and after obtaining written informed consent, we studied 21 patients with type 2 diabetes. Patients were recruited from the Bertram Diabetes Center, Norwich, U.K. (a secondary care diabetes facility), or from local primary care services if they were nonsmokers aged between 40 and 70 years and treated with diet or oral hypoglycemic agents alone. Patients were considered to have type 2 diabetes if they had been diagnosed after the age of 40 years, had no history of ketosis, and had stable glycemic control on diet or oral hypoglycemic agents for at least 6 months. Patients with clinical evidence of coronary artery disease (history of previous myocardial infarction or angina) and those receiving insulin were excluded. Patients with microalbuminuria (defined as an elevated urine albumin-to-creatinine ratio >2.5 for men and >3.5 for women) or macroproteinuria (defined as albustix-positive proteinuria) were excluded. Patients omitted all oral hypoglycemic agents or other medication on the morning of testing and fasted for 15 h before glucose tolerance tests were undertaken. All type 2 diabetic patients managed with diet alone had a fasting venous plasma glucose >7.0 mmol/l. Clinical details are shown in Table 1.

    Glucose tolerance tests and glycemic control

    All patients underwent a single glucose tolerance test (75 g oral anhydrous glucose) at 0800, with peripheral blood samples taken at 0, 60, 90, and 120 min from an indwelling venous cannula. Patients remained seated throughout the glucose tolerance test. HbA1c was assessed using a commercially available kit (Roche, Welwyn, U.K.) on an automated biochemistry analyzer (Cobas Mira; Roche), with the normal range quoted as 4.5–5.7%.

    Intracellular oxidative balance

    The intracellular glutathione (GSH) redox cycle between reduced GSH and oxidized GSH is an effective mechanism in protecting against intracellular oxidative damage because GSH acts as substrate for antioxidant enzymes and as a free radical scavenger, and the ratio of reduced-to-oxidized GSH by mass can be used as an index of intracellular oxidative stress (13). A 15-ml sample of whole blood was collected into EDTA, diluted to twice the original volume with PBS, and layered onto a 15 ml lymphocyte separation medium (ICN Biomedicals, Basingstoke, UK). It was then centrifuged at 390g for 30 min at 20°C. The lymphocyte layer was removed and washed twice with PBS, and the cell pellet was resuspended and an aliquot removed for cell counting. GSH was extracted from the lymphocyte pellet and measured using an enzymatic recycling method (14) modified for an automated biochemistry analyzer (Cobas Mira). This ratio was measured at 0 and 90 min during each glucose tolerance test and expressed as a ratio of reduced to oxidized GSH. The 90-min time point was chosen as being peak hyperglycemia and, by extension, the time point most likely to demonstrate changes in hyperglycemia-associated oxidative stress

    Plasma F2α isoprostane concentrations

    The determination of 8-epi-prostaglandin F2α (8-epi-PGF 2α) was based on previously described methodology (11,15). Peripheral venous blood (10 ml) was collected into polyethylene tubes containing a 3.8% (wt/vol) trisodium citrate solution (blood-to-anticoagulant ratio of 9:1) with indomethacin (as a cyclooxygenase inhibitor) and butylated hydroxytoluene (BHT; as a free radical scavenger) at final concentrations of 14 and 20 μmol/l, respectively. The sample was allowed to stand for 30 min at 4°C to enable complete inhibition of cyclooxygenase enzymes. Platelet-poor plasma was obtained by centrifugation at 1,120g for 15 min at 4°C. The plasma was transferred to a polypropylene screw-cap tube, and BHT was added at a final concentration of 20 μmol/l. The sample was then stored at −80°C until analysis. For determination of plasma total antioxidant status (TAOS), blood (5 ml) was collected in EDTA tubes and centrifuged at 1,120g for 15 min at 4°C. The plasma was transferred to screw-cap polypropylene tubes and stored at −80°C until analysis. Plasma samples were subjected to alkaline hydrolysis for the measurement of total (sum of free plus esterified) 8-epi-PGF2α by GC/MS. Plasma (0.5 ml) was transferred to a glass tube, followed by the addition of 8-epi-PGF2-d4 as an internal standard (2 ng in 20 ml ethanol). The sample was hydrolyzed with 1.0 mol/l aqueous potassium hydroxide (0.5 ml) for 30 min at 40°C. Hydrolysis was terminated by the addition of 0.1 mol/l hydrochloric acid (4.25 ml), and the pH of the sample was adjusted to 7.4 using 0.05 mol/l sodium phosphate buffer (4.5 ml). Isolation of 8-epi-PGF was carried out by immunoaffinity extraction of the hydrolyzed plasma. Samples were loaded on an immunoaffinity cartridge (prepared with an anti–8-epi-PGF2 antiserum) preconditioned with 16 ml sodium phosphate buffer (0.05 mol/l, pH 7.4). The cartridge was washed with water (20 ml) to remove nonretained components, and 8-epi-PGF2 was eluted using an acetone and water mixture (95:5 dilution, 5.5 ml). The immunoaffinity extraction steps were programmed into an Aspec XL sample processor (Gilson Medical Electronics, Villiers-le-Bel, France) and run automatically. The final eluate from the immunoaffinity extraction was dried under nitrogen and the sample converted to a perfluorobutyl/trimethylsilyl (PFB/TMS) derivative. Samples were analyzed by GC/negative ion chemical ionization/MS using an Autosystem XL GC coupled to a TurboMass MS (Perkin-Elmer, Beaconsfield, U.K.), with ammonia as reagent gas. The GC/MS assay has a limit of detection of ∼10 pg/ml (28 pmol/l) in plasma, with an intra- and interassay coefficient of variation of 4.4 and 7.6%, respectively. Analysis was performed using selected ion recording of the carboxylate anion [M-181] at m/z 569 for 8-epi-PGF2α and m/z 573 for 8-epi-PGF-d4. Quantitative determination was based on the peak height ratio of 8-epi-PGF2α against the internal standard. The isolation of 8-epi-PGF2α from plasma is based on the specific interaction between 8-epi-PGF2α and polyclonal anti–8-epi-PGF2α antibodies, prepared by raising antisera against 8-epi-PGF2α. After derivatization of the immunoextracted material, quantitation of 8-epi-PGF2α was carried out by stable-isotope dilution GC/MS with selected ion recording. The measurement of 8-epi-PGF2α provides a direct index of lipid peroxidation on phospholipid membranes in vivo and reflects oxidative processes within this environment. Oxidative stress due to hyperglycemia is associated with the increased generation of oxygen-derived radicals, and it is this change in free radical–mediated oxidation that is measured through the analysis of F2-isoprostanes. The nature of this assay makes it exceptionally unlikely (if not impossible) that direct interference by plasma glucose or insulin concentrations in vivo can occur; indeed, these types of assays are particularly valuable simply because they are not subject to interference from other constituents present in the assay mix. Plasma concentrations of 8-epi-PGF2α can be expressed in absolute amounts or normalized to plasma total arachidonic acid. Normalized concentrations of 8-epi-PGF2α are useful in situations where significant changes in the lipid profile or plasma fatty acids are expected, and they are unlikely to provide further information where intervention is limited to an isolated oral glucose load because even a high-calorie/high–saturated fat meal does not influence postprandial plasma total arachidonic levels (16).

    TAOS plasma assay

    The total antioxidant status of plasma was determined by its capacity to inhibit the peroxidase-mediated formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid (ABTS +) radical. In this assay, the relative inhibition of ABTS + formation in the presence of plasma is proportional to the antioxidant capacity of the sample. Briefly, plasma (2.5 μl) was incubated for 3 min at 37°C in a 96-well plate with a reaction mixture made up of (final concentrations) 20 μl ABTS (20 mmol/l), 20 μl horseradish peroxidase (30 mU/ml), and 37.5 μl PBS (pH 7.4). The reaction was started by the addition of 20 ml hydrogen peroxide (final concentration 0.1 mmol/l), and the increase in absorbance over 6 min was monitored at 405 nm, using a microplate reader (model 12605; Anthos Labtech, Salzburg, Austria). At the end of 6 min, the absorbance due to the accumulation of ABTS + in the test sample was read along with a control (containing 2.5 μl PBS instead of plasma). The difference in absorbance (control absorbance minus test absorbance), divided by the control absorbance (expressed as a percentage) was used to represent the percentage inhibition of the reaction.

    Measurement of lipid fractions

    Plasma lipid profiles were measured at time 0 and 90 min during each glucose tolerance test. Lipid profiles were assessed using commercially available kits (Roche) on an automated biochemistry analyzer (Cobas Mira; Roche), with estimation of LDL cholesterol (17).

    Statistical analysis

    Data are shown as the means ±1 SD, and all variables were normally distributed. Differences in individual variables measured more than twice during glucose tolerance test were analyzed by repeated-measure one-way ANOVA, with paired t tests where a significant difference (P < 0.05) was found. Otherwise, paired t tests were used for paired measurements. Relationships between variables were analyzed by simple linear regression or stepped multiple regression analysis with entry at P < 0.1. Data were analyzed using Apple Macintosh Statview software (1996).

    RESULTS

    Clinical details

    Clinical details are shown in Table 1. Of the diabetes group, 17 (81%) were taking metformin or a metformin-sulfonylurea combination. Seven patients (33%) were taking gliclazide, either alone or in combination with metformin, and seven (33%) were taking antihypertensive medication (Tables 1 and 2).

    Oxidative balance during glucose tolerance test

    There were no significant changes in the intracellular oxidative balance measured by reduced-to-oxidized GSH ratio or in the plasma total antioxidant status (P=0.1) (Table 2).

    Plasma 8-epi-F2α isoprostane concentrations in type 2 diabetes

    There was a highly significant (P=0.0102) rise in plasma 8-epi-F2α isoprostane concentrations between baseline and 90 min. There were no significant relationships between baseline plasma 8-epi-F2α isoprostane concentrations and HbA1c (r=0.32, P=0.15), fasting plasma glucose (r=0.33, P=0.13), or measures of intracellular oxidative balance and total antioxidant capacity (both P > 0.2). Peak plasma 8-epi-F2α isoprostane concentrations were directly related only to TAOS at 90 min (r=−0.495, P=0.025). Stepwise multiple regression demonstrated that only TAOS at 90 min was independently and inversely related to peak plasma 8-epi-F2α isoprostane (R2=0.248, P=0.025). Finally, the only variable independently inversely related to the absolute change in plasma 8-epi-F2α isoprostane concentrations during the glucose tolerance test was TAOS at 90 min (r=−0.45, P=0.041), and when the upper tertile of the 8-epi-F2α isoprostane increment was compared with the lower tertile, only TAOS at 90 min differed between tertiles (47.8± 10.4 vs. 62.9± 15.7%, respectively; P=0.023) (Table 2).

    CONCLUSIONS

    The main finding of this study is that acute hyperglycemia after a glucose load in type 2 diabetes is associated with an acute increase in plasma concentrations of 8-epi-F2α isoprostane. This must indicate increased free radical–mediated generation of these compounds from arachidonic acid in membrane and lipoprotein phospholipids (8–12). This provides sensitive and direct evidence for a link between acute rather than chronic hyperglycemia and free radical damage in type 2 diabetes.

    Changes in oxidative balance, or in antioxidant defenses, during acute hyperglycemia have been demonstrated before in subjects with and without type 2 diabetes (18–21). Increased LDL oxidizability induced by copper ions (22,23) has also been reported postprandially in type 2 diabetes, although the difficulties with this methodology have been reviewed (7), as has the confounding effect of dietary oxidized lipids (24). However, these measurements are surrogates, and the present study demonstrates directly increased plasma levels of a free radical–generated oxidation product of membrane arachidonic acid during acute hyperglycemia, independent of dietary intake of oxidized lipids or dietary isoprostane intake (25). Increased generation of reactive oxygen species is a feature of hyperglycemia in type 2 diabetes and impaired glucose tolerance (5,26), and the increased free radical damage during acute hyperglycemia demonstrated in this study occurred without significant changes in intracellular oxidative balance or plasma antioxidant capacity. That plasma total antioxidant capacity was the sole independent determinant of the increase in 8-epi-F2α isoprostane may suggest that acute increases in free radical generation during hyperglycemia do not influence TAOS, but that it is limited by the variety of antioxidant defenses contributing to the TAOS measurements. It is also possible that the TAOS and GSH assays are less sensitive for detecting changes in oxidative balance or stress compared with the 8-epi-F2α isoprostane assay used here, or that changes in TAOS and intracellular oxidative balance occurred before the 90-min sampling point used in this study.

    Plasma F2 isoprostane concentrations increased by 34% during acute hyperglycemia, and this is similar to observations in other models of increased oxidative damage. For example, Morrow et al. (9) demonstrated increased plasma esterified 8-epi-F2α isoprostane in heavy smokers, and smoking cessation led to a 24% reduction in mean 8-epi-F2α isoprostane concentration within a few weeks. 8-Epi-F2α isoprostane may also have biologically important proatherogenic actions, as well as being a marker for free radical damage. In vitro, 8-epi-F2α isoprostane at physiological concentrations promotes increased message and protein for endothelin-1 (27), promotes platelet adhesion to collagen in a dose-dependent manner (28), and antagonizes some actions of nitric oxide (29). Also, increased levels of 8-epi-F2α isoprostane are detectable in human coronary atherosclerotic plaque (29), particularly in smokers with increased oxidative damage rather than patients with treated hypertension or dyslipidemia (30), suggesting that 8-epi-F2α isoprostane generation may occur within coronary plaque.

    Metanalysis of available epidemiological and prospective studies has shown a consistent direct relationship between blood glucose levels and predominantly cardiovascular mortality (31) in type 2 diabetes, but some data suggest postprandial hyperglycemia may be an independent predictor of cardiovascular mortality in type 2 diabetes (1–3), and surrogates for macrovascular disease, such as carotid intimal-medial thickness, are more closely related to acute rather chronic hyperglycemia (32), and much of the controversy over the diagnostic classification of diabetes was based on the predictive power of post–glucose load hyperglycemia as a marker for increased vascular risk (33). The present data suggest one possible pathway for this association, by demonstrating increased free radical damage during acute hyperglycemia. This could promote an increase in vascular event rates through some of the mechanisms outlined above, or through proatherogenic processes sensitive to reactive oxygen species, such as increased adhesion molecule expression or coronary plaque metalloproteinase expression (34,35).

    The present study demonstrates that acute hyperglycemia in type 2 diabetes is associated with a significant increase in free radical–mediated damage to membrane components, measured by plasma 8-epi-F2α isoprostane concentrations, and this may be a link between acute hyperglycemia, increased free radical damage, and macrovascular risk in type 2 diabetes.

    View this table:
    • View inline
    • View popup
    Table 1—

    Baseline data

    View this table:
    • View inline
    • View popup
    Table 2—

    Changes in oxidative balance and plasma 8-epi-F2α isoprostane during a glucose tolerance test in 21 subjects with type 2 diabetes

    Acknowledgments

    We are grateful to Drs. Greenwood, Heyburn, and Temple for allowing access to their patients, and to the Norwich and Norfolk Diabetes Trust for funding salary costs associated with this project.

    Footnotes

    • Address correspondence and reprint requests to Dr. M.J. Sampson, Department of Endocrinology and Diabetes, Norfolk and Norwich University Hospital NHS Trust, Brunswick Rd., Norwich NR1 3SR, U.K. E-mail: mike.sampson{at}norfolk-norwich.thenhs.com.

      Received for publication 25 July 2001 and accepted in revised form 30 November 2001.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • DIABETES CARE

    References

    1. ↵
      Hanefeld M, Julius U, Schmechel H, Schwanebeck U: Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: the Diabetes Intervention Study (DIS) (Abstract). Atherosclerosis 151 (Suppl. 1): 1, 2000
      OpenUrlPubMed
    2. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22:696–699, 1999
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Balkau B, Eschwege E, Papoz L, Richard J-L, Claude J-R, Warnet J-M: Risk factors for early death in NIDDM and men with known glucose tolerance status. Br Med J 307:295–299, 1993
    4. ↵
      Lefebvre PJ, Scheen AJ: The postprandial state and risk of cardiovascular disease. Diabet Med 15 (Suppl. 4):S63–S68, 1998
    5. ↵
      Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications (Review). Diabetes Care 3:257–267, 1996
      OpenUrl
    6. ↵
      Delmas-Beauvieux MC, Peuchant E, Thomas MJ: The place of electron spin resonance methods in the detection of oxidative stress in type 2 diabetes with poor glycemic control. Clin Biochem 31:221–228, 1998
      OpenUrlPubMed
    7. ↵
      Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease an overview (Review). Methods Enzymol 186:1–85, 1990
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, Awad JA, Roberts LJ: The isoprostanes: unique prostaglandin like products of free radical initiate lipid peroxidation. Drug Metab Rev 31:117–139, 1999
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 332:1198–1203, 1995
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA: Plasma and urinary 8 isoprostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci 91:711–718, 1996
      OpenUrlPubMed
    11. ↵
      Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J: Plasma 8-epi-PGF 2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett225–229, 1995
    12. ↵
      Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229, 1999
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Nemeth I, Boda D: The ratio of oxidised: reduced glutathione as an index of oxidative stress in various experimental models of shock syndrome. Biomed Biochim Acta 48:S53–S57, 1989
      OpenUrlPubMedWeb of Science
    14. ↵
      Baker MA, Cerniglia GJ, Zaman A: Microtiter palate assay for the measurement of glutathione: and glutathione disulfide in large numbers of biological samples. Anal Biochem 190:360–365, 1990
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE: Analysis Of F2-isoprostanes as indicators of nonezymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 667:199–208, 1995
      OpenUrlCrossRefPubMed
    16. ↵
      Gopaul NK, Zacharowski K, Halliwell B, Änggård EE: Evaluation of the postprandial effects of a fast-food meal on human plasma F2-isoprostane levels. Free Rad Biol Med 28:806–814, 2000
      OpenUrlCrossRefPubMedWeb of Science
    17. ↵
      Friedewald WT, Levy RI, Frederikson DS: Estimation of the concentration of LDL cholesterol: in plasma without the use of the preparative centrifuge. Clin Chem 18:499–502, 1972
      OpenUrlAbstract/FREE Full Text
    18. ↵
      Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A: Meal generated oxidative stress in type 2 diabetic patients. Diabetes Care 21:1529–1533, 1998
      OpenUrlAbstract/FREE Full Text
    19. Ceriello A, Bortolotti N, Crescentini A: Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28:329–333, 1998
      OpenUrlCrossRefPubMedWeb of Science
    20. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T: The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest 20:471–475, 1998
      OpenUrlWeb of Science
    21. ↵
      Tessier D, Khalil A, Fulop T: Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. Gerontol A Biol Sci Med Sci 54:M541–M545, 1999
      OpenUrlAbstract/FREE Full Text
    22. ↵
      Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503–1508, 1999
      OpenUrlCrossRefPubMedWeb of Science
    23. ↵
      Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low density lipoproteins in type 2 diabetes are oxidised more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 222:178–184, 1999
      OpenUrlAbstract/FREE Full Text
    24. ↵
      Staprans I, Hardman DA, Pan XM, Feingold KR: Effect of oxidised lipids in the diet on oxidised lipid levels in postprandial serum chylomicrons of diabetic patients. Diabetes Care 22:300–306, 1999
      OpenUrlAbstract/FREE Full Text
    25. ↵
      Gopaul NK, Halliwell B, Anggard EE: Measurement f plasma F2-isoprostanes as an index f lipid peroxidation does not appear to be confounded by diet. Free Radic Res 33:115–127, 2000
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      Laight DW, Carrier MJ, Anggard EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 15:274–282, 1999
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A: Free radical generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 56:471–478, 1999
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, Lechi C: The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 18:1248–1256, 1998
      OpenUrlAbstract/FREE Full Text
    29. ↵
      Gniwotta C, Morrow JD, Roberts LJ, Kuhn H: Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17:3236–3241, 1997
      OpenUrlAbstract/FREE Full Text
    30. ↵
      Oguogho A, Karanikas G, Kritz H, Riehs G, Wagner O, Sinzinger H: 6-Oxo-PGF1alpha and 8-epi-PGF 2alpha in human atherosclerotic vascular tissue. Prostaglandins Leukot Essent Fatty Acids 60:129–134, 1999
      OpenUrlCrossRefPubMedWeb of Science
    31. ↵
      Groeneveld Y, Petri H, Hermans J, Springer MP: Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 16:12–13, 1999
    32. ↵
      Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830–1834, 2000
      OpenUrlAbstract/FREE Full Text
    33. ↵
      DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621, 1994
    34. ↵
      Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92:1866–1874, 1993
    35. ↵
      Galis ZS, Asanuma K, Godin D, Meng X: N-acetyl-cysteine: decreases the matrix degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97:2445–2453, 1998
      OpenUrlAbstract/FREE Full Text
    View Abstract
    PreviousNext
    Back to top
    Diabetes Care: 25 (3)

    In this Issue

    March 2002, 25(3)
    • Table of Contents
    • About the Cover
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes Care.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Plasma F2 Isoprostanes
    (Your Name) has forwarded a page to you from Diabetes Care
    (Your Name) thought you would like to see this page from the Diabetes Care web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Plasma F2 Isoprostanes
    Michael J. Sampson, Nitin Gopaul, Isabel R. Davies, David A. Hughes, Martin J. Carrier
    Diabetes Care Mar 2002, 25 (3) 537-541; DOI: 10.2337/diacare.25.3.537

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Plasma F2 Isoprostanes
    Michael J. Sampson, Nitin Gopaul, Isabel R. Davies, David A. Hughes, Martin J. Carrier
    Diabetes Care Mar 2002, 25 (3) 537-541; DOI: 10.2337/diacare.25.3.537
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • CONCLUSIONS
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes
    • High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
    • Restoration of Hypoglycemia Awareness Alters Brain Activity in Type 1 Diabetes
    Show more Pathophysiology/Complications

    Similar Articles

    Navigate

    • Current Issue
    • Standards of Care Guidelines
    • Online Ahead of Print
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.